Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegeneRx Biopharmaceuticals, Inc. (RGRX) TB4 Treatment Shown To Provide Both Neuroprotection And Neurorestoration After Traumatic Brain Injury In Rat Model

|Includes: RegeneRx Biopharmaceuticals, Inc. (RGRX)

RegeneRx Biopharmaceuticals stated that data regarding their novel, therapeutic peptide, Thymosin beta 4 (TB4), was published in the May 2012 edition of the Journal of Neurosurgery, 116:1081-1092. The data shows that TB4 "provides both neuroprotection and neurorestoration after traumatic brain injury (NYSE:TBI)."

The aims of the study were to test if TB4 treatment decreases brain damage and improves functional recovery in rats if the treatment is initiated 6 hours after traumatic brain injury. The research team states, "Compared with saline administration, TB4 treatment initiated 6 hours postinjury significantly improved sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell loss, and enhanced cell proliferation and neurogenesis in the injured hippocampus. Thymosin B4 treatment initiated 6 hours postinjury provides both neuroprotection and neurorestoration after TBI, indicating that TB4 has promising therapeutic potential in patients with TBI."

"These results are extremely encouraging and are consistent with results of TB4 administration in other Central nervous system injuries, as well as in cardiovascular injury models. Moreover, the reduction of brain damage, improved motor function, and regeneration of injured brain tissue, when TB4 is administered 6 hours after TBI, suggest that it could potentially be useful for the treatment of brain traumas seen in the military, the workplace and in contact sports," stated Dr. Allan Goldstein, Professor and Chairman Emeritus, Department of Biochemistry and Molecular Biology, The George Washington University School of Medicine, Washington, D.C. Dr. Goldstein is also chairman of and chief scientific advisor to RegeneRx.

The research team consisted of Xiong Y, Zhang Y, Mahmood A, Meng Y, Zhang ZG, Morris DC, and Chopp MJ. The researchers are from the Departments of Neurosurgery, Neurology, and Emergency Medicine at the Henry Ford Hospital System (HFHS), in Detroit, Michigan, and Department of Physics, Oakland University, in Rochester, Michigan, in accordance with a material transfer agreement between the RegeneRx Biopharmaceuticals, Inc. and Henry Ford Hospital.

For more information, please visit regenerx.com

Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net